兴业医疗保健A（011466）基金经理为陈旭。 截至发稿，陈旭累计任职时间4年299天，现任基金资产总规模4.04亿元，任职期间最佳基金回 报-20.35%， 任职期间最差基金回报-22.24%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 12月30日，东诚药业跌1.03%，截至发稿，报13.49元/股，成交1140.86万元，换手率0.11%，总市值 111.24亿元。 资料显示，烟台东诚药业集团股份有限公司位于山东省烟台经济技术开发区长白山路7号，成立日期 1998年12月31日，上市日期2012年5月25日，公司主营业务涉及肝素钠原料药、硫酸软骨素的研发、生 产和销售。主营业务收入构成为：原料药相关产品44.16%，核药产品36.38%，制剂产品13.17%，其他 6.30%。 从基金十大重仓股角度 数据显示，兴业基金旗下1只基金重仓东诚药业。兴业医疗保健A（011466）三季度持有股数123.49万 股，占基金净值比例为4.65%，位居第 ...

Group 1 - Dongcheng Pharmaceutical's stock increased by 5.01%, reaching 15.50 CNY per share, with a trading volume of 201 million CNY and a turnover rate of 1.78%, resulting in a total market capitalization of 12.781 billion CNY [1] - The company, established on December 31, 1998, and listed on May 25, 2012, specializes in the research, production, and sales of heparin sodium raw materials and chondroitin sulfate [1] - The revenue composition of Dongcheng Pharmaceutical includes 44.16% from raw materials, 36.38% from nuclear medicine products, 13.17% from formulations, and 6.30% from other sources [1] Group 2 - According to data, one fund under Industrial Bank holds Dongcheng Pharmaceutical as a significant investment, with 1.2349 million shares, accounting for 4.65% of the fund's net value, making it the sixth-largest holding [2] - The fund, named Industrial Medical Care A (011466), has a current scale of 261 million CNY and has achieved a year-to-date return of 22.76%, ranking 4158 out of 8154 in its category [2] - The fund has a one-year return of 14.98%, ranking 5070 out of 8046, and has experienced a cumulative loss of 20.27% since its inception [2]

Core Viewpoint - Zai Jian Pharmaceutical's stock increased by 5.09% to 91.43 CNY per share, with a market capitalization of 24.202 billion CNY as of October 30 [1] Company Overview - Suzhou Zai Jian Biopharmaceutical Co., Ltd. was established on March 18, 2009, and went public on January 23, 2020 [1] - The company's main business involves the research, production, and sales of chemical new drugs and biological new drugs, with 99.97% of revenue coming from pharmaceuticals [1] Fund Holdings - One fund under Industrial Bank, the Industrial Medical Care A (011466), holds 143,000 shares of Zai Jian Pharmaceutical, unchanged from the previous period, representing 4% of the fund's net value [2] - The fund has a total size of 261 million CNY and has achieved a year-to-date return of 24.05% [2] - The fund manager, Chen Xu, has been in position for 4 years and 238 days, with the best and worst fund returns during his tenure being -19.16% and -21.01%, respectively [2]

Core Insights - Tonghua Dongbao Pharmaceutical (300636.SZ) released its Q3 2025 report on October 25, 2025, indicating a total of 63.9184 million A-shares held by three institutional investors, accounting for 15.22% of the company's total share capital [1] - The institutional holding percentage decreased by 1.80 percentage points compared to the previous quarter [1] Institutional Investors - The three institutional investors include: - Fong Lung Industrial Co., Ltd. - Guotai Junaq Securities' special pension product from China Merchants Bank - Jiangxi Chinese Media Blue Ocean International Investment Co., Ltd. [1] - The total institutional holding ratio stands at 15.22% [1] Public Funds - A total of 58 public funds were not disclosed in the current period compared to the previous quarter, including: - Galaxy Medical Mixed A - Industrial Bank Healthcare A - Galaxy Kang Le Stock A - Fuanda Medical Innovation Mixed - Xiangcai Medical Health Mixed A [1]

Core Viewpoint - The stock of Zhejiang Sitaili Pharmaceutical Co., Ltd. experienced a 6.12% increase, reaching 12.65 CNY per share, with a total market capitalization of 5.546 billion CNY as of September 15 [1] Group 1: Company Overview - Zhejiang Sitaili Pharmaceutical Co., Ltd. was established on September 15, 1997, and went public on March 9, 2016 [1] - The company specializes in the production and sales of non-ionic iodine contrast agent raw materials and quinolone raw materials [1] - The revenue composition of the company includes: contrast agents 79.73%, other supplementary products 10.19%, other 6.16%, CMO/CDMO 2.41%, and quinolone series 1.52% [1] Group 2: Fund Holdings - One fund, Xingye Healthcare A (011466), holds a significant position in Sitaili, with 1.8991 million shares, accounting for 4.83% of the fund's net value, making it the sixth-largest holding [2] - The fund has achieved a year-to-date return of 36.14% and a one-year return of 49.23%, ranking 1872 out of 8246 and 3177 out of 8054 in its category, respectively [2] - The fund manager, Chen Xu, has been in position for 4 years and 193 days, with a total fund size of 385 million CNY [2]